ABSTRACT Pentazocine and its related compounds were examined for their effect on the cytotoxicity of cortisone-resistant lymphocytes (CR lymphocytes) against Ehrlich carcinoma cells. The following compounds were used: pentazocine, naloxone, levallorphan, eptazocine and morphine. CR lymphocytes were obtained from the thymus or spleens of mice injected i.p. with hydrocortisone acetate (125 mg/kg) 2 days before harvesting the lymphocytes. The mixture of tumor cells and CR lymphocytes was inocu lated s.c. into mice after incubation in the presence or absence of 10 pM drugs. Five weeks after the in oculation, the percentage of mice developing a solid tumor among the recipients given the pentazocine treated cell mixture of tumor cells and thymic CR lymphocytes was significantly smaller than the per centage in recipients given the cell mixture treated with or without other drugs (percent tumor takes: 21% and about 80%, respectively). Splenic CR lymphocytes did not show any cytotoxic effect, irrespec tive of the drug treatment. The pretreatment of CR lymphocytes or Ehrlich cells with 10,uM pentazo cine did not affect the cytotoxicity of thymic and splenic CR lymphocytes. The proportion of the lymphocyte-conjugated tumor cells was significantly increased when the mixture of CR lymphocytes and tumor cells was incubated in the presence of pentazocine. The present results indicate that the cyto toxicity of thymic CR lymphocytes is enhanced by pentazocine possibly through the increase in the pro portion of the lymphocyte-conjugated tumor cells but enhanced not by the other drugs.
It has been well-established that the treatment of mice with corticosteroids results in a rapid atrophy of the thymus and spleen and a pronounced decrease of lymphocytes in these lymphoid tissues (1) . The lympho cytes remaining in the lymphoid tissues of mice after treatment with hydrocortisone are known as the cortisone-resistant lymphocytes (CR lymphocytes), which are abundant in T cells, and are cytotoxic to tumor cells or allogeneic cells (2) (3) (4) (5) . We have revealed that the cytotoxicity of CR lymphocytes is enhanced by the treatment of the donor mice for CR lymphocytes with group A streptococcus or Freund's complete ad juvant (5) .
Many studies have demonstrated that opioid peptides are involved in the immune systems, such as the pro duction of antibody or interleukin-2, the proliferation of blood lymphocytes by lectins or the activity of natu ral killer cells (6, 7) . In addition, there are several re ports dealing with the effect of morphine and its ana logues on the lymphocyte transformation by lectins, the rosette formation of T cells or the hemolysin produc tion by lymphocytes (8, 9) . However, little is known about the effect of morphine and its analogues on the cytotoxicity of T lymphocytes.
The present study was performed to examine the effect of morphine and its analogues on the cytotoxicity of CR lymphocytes against Ehrlich carcinoma cells. We found that among the morphine-related compounds, pentazocine enhanced the cytotoxicity of thymic lym phocytes with an increase in the proportion of CR lymphocyte-conjugated tumor cells.
MATERIALS AND METHODS

Drugs
The drugs used were as follows: pentazocine (15 mg/ml solution, Sankyo Co.), naloxone hydrochloride (0.2 mg/ml solution, Sankyo Co.), levallorphan tartrate (1 mg/ml solution, Takeda Chem. Indust.), eptazocine hydrochloride (15 mg/ml solution, Kaken Pharmaceut.
Co.) and morphine hydrochloride (Takeda Chem. In dust.), which was dissolved in physiological saline.
Preparing the cell suspension
The animals used were 7 8-week-old female mice of the ddY strain (Shizuoka Laboratory Animal Center). To obtain cortisone-resistant lymphocytes (CR lympho cytes), a total of 80 mice in a group was injected i.p. with 125 mg/kg of hydrocortisone acetate (Schering AG) 2 days before killing (3, 10) . The suspension of CR lymphocytes was prepared from the thymus or spleen of the mice, using Hanks balanced salt solution (HBSS). The lymphocyte suspension contained 93 98% of lymphocytes and 2-6% of macrophages, and about 95% of the cells in the suspension were viable according to the trypan blue test.
Ehrlich carcinoma cells were obtained from mice at 10 days after i.p.-inoculation of the tumor cells, and they were suspended in HBSS (11) . In the tumor cell suspension, 85 90% of cells were viable according to the trypan blue test.
Test for the direct cytotoxicity of the drugs
To examine the effect of drugs on Ehrlich carcinoma cells, the tumor cells were suspended in HBSS sup plemented with 2% bovine albumin fraction V (Armour Pharmaceut. Co.) (albumin-HBSS), and then they were incubated at 37°C for 120 min with or without 10 p M drugs (2 X 106 cells/ml) (11) . After the incubation, the tumor cells were resuspended in HBSS and inoculated s.c. into the right flank of mice (106 cells/mouse). The growth of solid tumors in the mice was observed for 5 weeks. In addition, the proportion of viable cells in the tumor cell suspension was examined after the incuba tion by the trypan blue test (11) .
Examination of the cytotoxicity of CR lymphocytes
The effect of CR lymphocytes against Ehrlich carci noma cells was examined by the Winn test, with a slight modification (5, 12) . The CR lymphocytes suspended in albumin-HBSS (5 X 106 lymphocytes/ml) were mixed with Ehrlich cells (tumor cells/lymphocytes: 1/10), and the cell mixture was incubated at 37°C for 30 to 120 min in the presence or absence of drugs. After incuba tion, the cell mixture resuspended in HBSS was inocu lated s.c. into the right flank of mice (106 tumor cells/mouse), and the growth of the solid tumor in the mice (recipient mice) was observed for 5 weeks. To evaluate the cytotoxicity of CR lymphocytes on the tumor cells, the percent of tumor takes was calculated for each group of recipient mice: Tumor takes (%) = (number of tumor-bearing mice/total inoculated mice) X 100.
In addition, the cytotoxicity of pentazocine-pre treated CR lymphocytes on Ehrlich carcinoma cells and that of CR lymphocytes on pentazocine-pretreated Ehrlich carcinoma cells were examined. For pretreating the cells, the CR lymphocytes or Ehrlich cells sus pended in albumin-HESS (5 X 106 lymphocytes/ml or 2 X 106 tumor cells/ml) were incubated with 10 ,u M pen tazocine at 37°C for 60 or 120 min, and these cells were washed twice in HBSS thereafter.
Examination of the tumor cells conjugated with lympho cytes
With reference to the cytotoxicity of CR lymphocytes on Ehrlich carcinoma cells, the proportion of the tumor cells conjugated with CR lymphocytes in the mixture of these two cells was examined (13) (14) (15) . The mixture of Ehrlich cells and CR lymphocytes (tumor cells/ lymphocytes: 1/10) in albumin-HBSS was incubated at 37°C for 15 to 90 min in the presence or absence of 10 p M drugs. After the incubation, the number of tumor cells conjugated with lymphocytes in the cell mixture was examined as follows: Smears of the cell mixture were fixed with methanol and stained by the Giemsa's method. The smears were then tested microscopically for the number of tumor cells conjugated with lympho cytes; a tumor cell with 1 to 3 lymphocytes adhering to it or two tumor cells connected by a lymphocyte were observed, and all such cells were judged to be conju gated tumor cells. To examine the effect of drugs on the conjugation, the proportion of the tumor cells con jugated with lymphocytes under treatment with a drug was calculated and compared with that without treat ment. The proportion of the tumor cells conjugated with lymphocytes (%) = (number of tumor cells conju gated with lymphocytes/number of tumor cells ex amined) X 100.
RESULTS
Direct effect of drugs on the viability of tumor cells
Before testing the drug effect on the cytotoxicity of CR lymphocytes, pentazocine and its related com pounds were examined for their direct effect on Ehrlich carcinoma cells. When the tumor growth was evaluated 5 weeks after the inoculation, no significant difference was observed in the growth of solid tumors among the groups of mice that were inoculated with Ehrlich cells treated with 10,uM of pentazocine, naloxone, levallor phan, eptazocine, morphine or no drug for 120 min be fore the inoculation (data not shown).
Effect of drugs on the cytotoxicity of CR lymphocytes
The effect of drugs on the cytotoxicity of CR lym phocytes was examined according to the modified Winn test described in the Methods section. Table 1 shows the number of tumor-bearing mice 5 weeks after the ino culation. When the mixture of Ehrlich cells and thymic CR lymphocytes was treated with 10 ,u M pentazocine for 120 min and then inoculated into mice, tumor takes were significantly smaller than those in the other groups of recipients (tumor takes: 21% and 79-83%, respec tively, P < 0.01). The effect of pentazocine was de pendent on the incubation time. No growth of the tumor was observed in a group of recipients given the cell mixture treated with 10,uM pentazocine for 180 min (Fig. 1A) .
On the other hand, splenic CR lymphocytes did not show any cytotoxic effect, irrespective of the drug treat ment. Tumor takes in groups of mice given the cell mixture treated with the drugs and without any drug for 120 min were 69 90% and 94%, respectively (Table 1 and Fig. 1B) . Table 1 and plotted on the ordinate. Asterisks indicate statistically significant differences from the value in the absence of pentazocine (P < 0.01 by the ;r2 concentration-dependence of the effect of penta zocine was examined. When the mixture of Ehrlich cells and thymic CR lymphocytes was treated for 120 min with 0.1-10 ,u M pentazocine before the inocula tion, tumor takes were decreased with an increase in the drug concentration (Fig. 2) . However, no significant enhancement of cytotoxicity was observed in the splenic CR lymphocytes treated with pentazocine. These results indicate that the enhancement of the cytotoxicity of CR lymphocytes on Ehrlich carcinoma cells is specific for the thymic CR lymphocytes and is produced by penta zocine in a concentration-dependent manner.
On the other hand, no enhancement was observed when either CR lymphocytes or tumor cells were pre treated with pentazocine before they were mixed together. As shown in Tables 2 and 3, tumor takes were not significantly different between the untreated groups and the groups in which CR lymphocytes or tumor cells were treated with pentazocine, irrespective of the origin of the CR lymphocytes.
Effect of drugs on the conjugation of tumor cells and CR lymphocytes
In connection with the effect of pentazocine on the cytotoxicity of CR lymphocytes, the proportion of Ehrlich carcinoma cells conjugated with CR lympho cytes (proportion of the conjugated tumor cells) was ex amined in the mixture of these two cells after incuba tion for 15 to 90 min in the presence or absence of pen tazocine (Fig. 3) . When the mixture of Ehrlich cells and CR lymphocytes from the thymus or spleen was incu bated with 10,uM pentazocine for 90 min, the propor tion of the conjugated tumor cells in the cell mixture was increased pronouncedly within 15 min, reached its highest level at 30 min and decreased thereafter (Fig. 3,  A and B) . The proportion of the conjugated tumor cells in the cell mixture treated with the other drugs or without any drug was also increased progressively with in 60 min, but the proportion was significantly lower than that in pentazocine-treated cells (Fig. 3 and Table  4 ).
The number of tumor cells in the cell mixture was smaller in the mixture of Ehrlich cells and thymic CR lymphocytes treated with 10,uM pentazocine for 90 min, as compared with that in the cell mixture treated with or without other drugs (tumor cells/200 lympho cytes: 11 ± 1 and 20 ± 1, n = 6). In the case of the splenic CR lymphocytes, however, there was no signifi cant difference in the number of tumor cells between the cell mixture treated with and without pentazocine for 90 min (tumor cells/200 lymphocytes: 20 ± 1 and 20 ± 1, n = 6). 
DISCUSSION
Pentazocine and its related compounds had no direct effect on the viability of Ehrlich carcinoma cells at a concentration of 10 ,u M. The result is consistent with our previous in vitro study in which there was only a slight difference in the proportion of viable cells among the groups of tumor cells treated with 10 MM pentazo cine, its related drugs and without a drug (11) .
The treatment of the mixture of Ehrlich cells and The present results suggest that pentazocine increases the proportion of CR lymphocyte-conjugated tumor cells when the cell mixture was incubated with the drug, resulting in the increase of the number of tumor cells to be lysed. The pretreatment of CR lymphocytes or Ehrlich cells with pentazocine did not enhance the cytotoxicity of CR lymphocytes. In addition, the proportion of the conjugated tumor cells differed slightly between the cell mixture containing the pentazocine-pretreated cells and that containing untreated cells (data not shown). Thus it is likely that pentazocine does not modify the nature of CR lymphocytes nor Ehrlich carcinoma cells to be more conjugative, but helps the conjugation of the lym phocytes and the tumor cells when the cell mixture is simultaneously incubated with pentazocine. The result also supports the conclusion that the conjugation of tumor cells with CR lymphocytes is important for the cytolysis of tumor cells in this effector-target cell sys tem.
Although pentazocine significantly increased the proportion of the CR lymphocyte-conjugated tumor cells when incubated with splenic CR lymphocytes, it did not enhance the cytotoxicity of the splenic CR lym phocytes. These results indicate the possible heter ogeneity of the CR lymphocytes. Heterogeneity in the mesenteric and splenic CR lymphocytes has been dem onstrated in our previous report (5) . The mechanisms responsible for the increase in the cytotoxicity of the CR lymphocytes by the treatment with pentazocine remain unclear. Phosphoinositide breakdown or protein kinase C activation may be re lated to the mechanisms, since activation of protein kinase C has been suggested to be involved in the cyto toxic action of T lymphocytes (18) . This point should be elucidated by further experiments.
Among the drugs tested, only pentazocine showed the enhancing effect on the cytotoxicity. The result may be explained by the difference in the chemical struc ture, since pentazocine differs markedly from mor phine, naloxone, levallorphan or eptazocine in its che mical structure (19) . There is little difference in the pharmacological properties between pentazocine and eptazocine (20) . Therefore, the effect of pentazocine on the cytotoxicity of thymic CR lymphocytes does not seem to be related to the pharmacological properties reported.
